Description
Pre-made Lentivirus express the CAR construct of “3xFLAG-anti-HER2-ScFV (VL-VH)-CD8 hinge-CD28-CD3ζ”. It does not contain any selection marker, trying to minimize the marker’s possible immunogenicity.
This CAR construct, contains the N-term 3xFLAG tagged “HER2-scFv [VH-(G4S)x4-VL]” recognition domain, linked to CD28 stimulatory domain, expressed under the enhance EF1a promoter. The lentivector’s core structure is represented by the scheme below.
HER2 (Human Epidermal Growth Factor Receptor 2 / ERBB2 / CD340) is a receptor protein involved in cell growth and division. HER2, overexpressed in some breast cancers, is a target for CAR-T therapy in certain breast cancers. This CAR’s recognition sequence uses the anti-human HER2 ScFV (clone RFP5) (Reference).
see details in Product Manual.
CD28, a transmembrane protein on T cells, provides co-stimulatory signals for T cell activation and proliferation. CD28 costimulatory domains in CARs enhance anti-malignancy efficacy, making it a common choice in CAR design.
CD3ζ (T-cell receptor zeta) is expressed by T cells and NK cells. It together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. CD3-zeta is the most commonly used activation component of CARs. It transmits an activation signal to the T cell after the antigen is bound. It can be coupled with additional co-stimulatory signaling for the complete activation.
Negative Controls: To validate the specificity of the targeted CAR-T killing, you can use the negative control CAR lentivirus: the CAR-ctr6 that has the same lentivector backbone but removed the recognition domain.
Amount: 200 ul/vial at titer of 1×108 IFU/ml, concentrated lentivirus provided in PBS solution, premixed with 10x polybrene (60ug/ml), premade, ready to ship in dry-ice package.
CAT#: LVP1656
